It became famous as a potential anticancer agent because it seemed to selectively induce apoptosis in cancer cells.3, 9 Although preclinical studies were promising, clinical trials applying either human recombinant TRAIL or agonistic antibodies revealed only a limited therapeutic benefit (summary of clinical studies in Lemke et al.9). The gene discussed is TNFSF10; the disease is cancer.